Junko Tanizaki

Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Keiichi Ota, Koichi Azuma, Akihiko Kawahara et al. · Clinical Cancer Research · 2015 · 428 citations · Full text

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Koji Haratani, Hidetoshi Hayashi, Taro Tanaka et al. · Annals of Oncology · 2017 · 291 citations · Full text

Tumor Immune Microenvironment, Cancer Immunosurveillance, Medicine +11

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer

Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi et al. · Clinical Cancer Research · 2020 · 233 citations

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi et al. · Journal of Thoracic Oncology · 2017 · 223 citations

Biomarker (Medicine), Prognostic Biomarkers, Oncology +9

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Li Tan, Jun Wang, Junko Tanizaki et al. · Proceedings of the National Academy of Sciences · 2014 · 175 citations · Full text

Covalent Inhibitors, Fgfr Inhibitors, Human Fgf Receptors +18